AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (195)	8/7/1997 2:22:00 PM
From: Dr. John M. de Castro	of 298

The MYLORAL MRI results are for the male DR2+ group. This is very puzzling as the Phase II MYLORAL trial found significant effects for the male DR2- group and no effect on the male DR2+ group. AIMM investor relations told me that this was a complete surprise to them. I was told that there would not be further releases on these data and that they had no intention of pursuing MYLORAL any further. However, they would be talking to other companies who might be interested in pursuing it. Their intent is to focus on COLORAL. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next